Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Loratadine

FDA-approved product (tablet, oral), marketed as Alavert, Children's Claritin, Claritin and 5 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Loratadine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic disease
  • Allergic rhinitis
  • Pruritus
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis
  • Urticaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antihistamines for systemic use
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Loratadine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Loratadine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients

    NCT02545361 · start 2018-04

    Registered record
    Registry ID
    NCT02545361
    Conditions
    Lymphoma
    Interventions
    KAHR-102
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2018-04
    Completion
    2020-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    InterventionKAHR-102
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure

    NCT03443843 · start 2018-02-21

    Registered record
    Registry ID
    NCT03443843
    Conditions
    Rhinitis, Allergic
    Interventions
    loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D); Placebo tablet; Fluticasone Propionate; Placebo spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-02-21
    Completion
    2018-05-11
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic
    Interventionloratadine + pseudoephedrine sulfate (BAY818725/Claritin-D); Placebo tablet; Fluticasone Propionate; Placebo spray
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients

    NCT03640273 · start 2017-11-23

    Registered record
    Registry ID
    NCT03640273
    Conditions
    Allergic Rhinitis; Adverse Drug Event; Quality of Life
    Interventions
    Prapchompoothaweep remedy; Loratadine 10 Mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-11-23
    Completion
    2018-06-24
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis; Adverse Drug Event; Quality of Life
    InterventionPrapchompoothaweep remedy; Loratadine 10 Mg
    PhasePhase 2
    Registry statusCompleted

  • MP-AzeFlu Allergen Chamber - Onset of Action Study

    NCT03004131 · start 2017-01-07

    Registered record
    Registry ID
    NCT03004131
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    Azelastine hydrochloride + fluticasone propionate nasal spray; Placebos; fluticasone propionate nasal spray + loratadine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-01-07
    Completion
    2017-03-29
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionAzelastine hydrochloride + fluticasone propionate nasal spray; Placebos; fluticasone propionate nasal spray + loratadine
    PhasePhase 4
    Registry statusCompleted

  • Effectiveness of Qufeng Shengshi Fang on Treatment of Allergic Rhinitis.

    NCT02653339 · start 2016-06

    Registered record
    Registry ID
    NCT02653339
    Conditions
    Rhinitis, Allergic, Perennial
    Interventions
    Qufeng Shengshi Fang and Loratadine; Loratadine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-06
    Completion
    2018-08
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial
    InterventionQufeng Shengshi Fang and Loratadine; Loratadine
    PhaseNot applicable
    Registry statusUnknown

  • Montelukast and Loratadine in Children With Asthma

    NCT03372473 · start 2016-01-10

    Registered record
    Registry ID
    NCT03372473
    Conditions
    Asthma in Children
    Interventions
    Montelukast mixed with Loratadine; Montelukast
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-10
    Completion
    2017-06-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma in Children
    InterventionMontelukast mixed with Loratadine; Montelukast
    PhasePhase 3
    Registry statusCompleted

  • To Assess Bioequivalence of Loratadine Oral Solution/Syrup Versus Claritin Peach Syrup

    NCT02593747 · start 2015-12

    Registered record
    Registry ID
    NCT02593747
    Conditions
    Histamine H1 Antagonists, Non-Sedating
    Interventions
    Loratadine oral solution; Loratadine (Claritin peach syrup)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-12
    Completion
    2016-03
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHistamine H1 Antagonists, Non-Sedating
    InterventionLoratadine oral solution; Loratadine (Claritin peach syrup)
    PhasePhase 1
    Registry statusCompleted

  • Study of Efficacy and Safety of Ginger Extract Compared With Loratadine for Treatment of Allergic Rhinitis

    NCT02576808 · start 2015-10

    Registered record
    Registry ID
    NCT02576808
    Conditions
    Rhinitis,Allergic
    Interventions
    Ginger extract; Loratadine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-10
    Completion
    2017-10
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis,Allergic
    InterventionGinger extract; Loratadine
    PhasePhase 2
    Registry statusCompleted

  • Effectivness and Safety of Acupuncture Combined With Moxibustion for Allergic Rhinitis

    NCT02339714 · start 2015-03

    Registered record
    Registry ID
    NCT02339714
    Conditions
    Rhinitis, Allergic, Perennial
    Interventions
    acupuncture combined moxibustion; Loratadine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-03
    Completion
    2018-06
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial
    Interventionacupuncture combined moxibustion; Loratadine
    PhasePhase 2
    Registry statusCompleted

  • Patient Experience Study of Deoxycholic Acid Injection

    NCT02007434 · start 2013-12

    Registered record
    Registry ID
    NCT02007434
    Conditions
    Moderate or Severe Submental Fullness
    Interventions
    Deoxycholic Acid Injection; Placebo; Cold Compress; Lidocaine / Epinephrine; Loratadine; Ibuprofen; Compression Chin Strap
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-12
    Completion
    2014-06
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate or Severe Submental Fullness
    InterventionDeoxycholic Acid Injection; Placebo; Cold Compress; Lidocaine / Epinephrine +3 more
    PhasePhase 3
    Registry statusCompleted

  • Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or Loratadine

    NCT02513290 · start 2013-08

    Registered record
    Registry ID
    NCT02513290
    Conditions
    Allergic Rhinitis
    Interventions
    Bilastine; Loratadine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-08
    Completion
    2014-08
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis
    InterventionBilastine; Loratadine
    PhasePhase 4
    Registry statusCompleted

  • A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)

    NCT01469234 · start 2011-10

    Registered record
    Registry ID
    NCT01469234
    Conditions
    Rhinitis
    Interventions
    loratadine; fexofenadine; placebo to loratadine; placebo to fexofenadine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-10
    Completion
    2011-11
    Enrolment
    255

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis
    Interventionloratadine; fexofenadine; placebo to loratadine; placebo to fexofenadine
    PhasePhase 4
    Registry statusCompleted

  • Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis.

    NCT01228630 · start 2011-08

    Registered record
    Registry ID
    NCT01228630
    Conditions
    Perennial Allergic Rhinitis
    Interventions
    Cloratadd-D; Allegra-D
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-08
    Completion
    2012-05
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerennial Allergic Rhinitis
    InterventionCloratadd-D; Allegra-D
    PhasePhase 3
    Registry statusCompleted

  • Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)

    NCT01413958 · start 2011-08

    Registered record
    Registry ID
    NCT01413958
    Conditions
    Seasonal Allergic Rhinitis
    Interventions
    Phenylephrine; Placebo; Loratadine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-08
    Completion
    2011-10
    Enrolment
    575

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Rhinitis
    InterventionPhenylephrine; Placebo; Loratadine
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)

    NCT01390441 · start 2011-07

    Registered record
    Registry ID
    NCT01390441
    Conditions
    Rheumatoid Arthritis
    Interventions
    MK-8808; MabThera® (rituximab); Methotrexate; Rituxan® (rituximab); Methylprednisolone; Acetaminophen; Loratadine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2011-07
    Completion
    2014-04
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionMK-8808; MabThera® (rituximab); Methotrexate; Rituxan® (rituximab) +3 more
    PhasePhase 1
    Registry statusTerminated